


Claims

1) Synthesised cyclosporin characterised by the formula:



| 1 2 3 4 5 6 7 8 9 10 11 |

wherein:

X is -MeBmt or 6,7-dihydro-MeBmt-

U is -Abu, Nva, Val, Thr

Y is Sar or (D)-MeSer or (D)-MeAla or (D)-MeSer (OAcyl)

Z is (N-R)aa where aa ≠ (Val, Ile, Thr, Phe, Tyr, Thr (OAc), Thr (OG₁), Phe (G₂), PheCH₂(G₃), Tyr (OG₃)) with R = (alkyl > CH₃);

G₁ = (phenyl-COOH, phenyl-COOMe, phenyl-COCEt);


G₂ = (CH₂COOH, CH₂COOMe(Et)₂, CH₂PO(OMe)₂, CH₂PO(OH)₂);

G₃ = (PO(OH)₂, PO(OCH₂CH=CH₂)₂, CH₂COOH, CH₂COOMe(Et)).

2) Cyclosporin according to claim 1, characterised in that the residue Z in position 4 is (R)Val where R>CH₃ and R<C₁₂H₂₅.

3) Cyclosporin according to any one of the preceding claims, characterised in that the residue Z in position 4 is N-ethyl-valine.

4) Pharmaceutical composition containing the compound characterised by the formula:



1 2 3 4 5 6 7 8 9 10 11 12

wherein:

X is -MeBmt or 6,7-dihydro-MeBmt-

U is -Abu, Nva, Val, Thr

Y is Sar or (D)-MeSer or (D)-MeAla or (D)-MeSer (OAcyl)

Z is (N-R)aa where aa=(Val, Ile, Thr, Phe, Tyr, Thr (OAc), Thr (OG₁), Phe (G₂), PheCH₂(G₃), Tyr (OG₃)} with R = {alkyl > CH₃};

G₁ = {phenyl-COOH, phenyl-COOMe, phenyl-COOEt};

G₂ = {CH₂COOH, CH₂COOMe(Et), CH₂PO(CMe)₂, CH₂PO(OH)₂};

G₃ = {PO(OH)₂, PO(OCH₂CH=CH₂)₂, CH₂COOH, CH₂COOMe(Et)}

- 5) Pharmaceutical composition according to claim 4, characterised in that it is combined with a pharmaceutically acceptable solution.
- 6) Use of the cyclosporin according to any one of the preceding claims for the production of a medicinal product intended for the treatment and prevention of AIDS.
- 7) Use of the cyclosporin according to claim 3 for the production of a medicinal product intended for the treatment and prevention of AIDS.